[
  {
    "ts": null,
    "headline": "Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs",
    "summary": "SAN JOSE, Calif., January 08, 2026--Today, Visby Medical announced two new relationships that will expand national access to the Visby Women’s Sexual Health Test, the first, at-home, FDA-authorized PCR test for sexually transmitted infections (STIs) available to consumers, enabling immediate access to Visby’s integrated \"Test-to-Treat\" ecosystem. The palm-sized device delivers confidential results in just 30 minutes, providing women with a rapid response for chlamydia, gonorrhea, and trichomonia",
    "url": "https://finnhub.io/api/news?id=ddba9ce49bc7636bf7e55232ae4701d4d3f02e051ea0f27f008ed3a33389e51c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767880800,
      "headline": "Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs",
      "id": 138037226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "SAN JOSE, Calif., January 08, 2026--Today, Visby Medical announced two new relationships that will expand national access to the Visby Women’s Sexual Health Test, the first, at-home, FDA-authorized PCR test for sexually transmitted infections (STIs) available to consumers, enabling immediate access to Visby’s integrated \"Test-to-Treat\" ecosystem. The palm-sized device delivers confidential results in just 30 minutes, providing women with a rapid response for chlamydia, gonorrhea, and trichomonia",
      "url": "https://finnhub.io/api/news?id=ddba9ce49bc7636bf7e55232ae4701d4d3f02e051ea0f27f008ed3a33389e51c"
    }
  },
  {
    "ts": null,
    "headline": "NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp",
    "summary": "NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide.",
    "url": "https://finnhub.io/api/news?id=611394a9851c8338a7a3845665ba97b68fe01551ff8f9269256a432a9fdfbe20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767879000,
      "headline": "NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp",
      "id": 138037227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide.",
      "url": "https://finnhub.io/api/news?id=611394a9851c8338a7a3845665ba97b68fe01551ff8f9269256a432a9fdfbe20"
    }
  }
]